1. Cryptogenic Stroke and PFO: The Hole Story: Anthony J Furlan MD Gilbert W Humphrey Professor Chairman Department of Neurology University Hospitals Case Medical Center

2. DISCLOSURES Principal Investigator –CLOSURE I NMT Medical, Boston

3. PFO in Embolic Stroke PFO in stroke: The principle is sound. How real is the problem? RALA P RA P LA

4. TEE

5. [Help with image viewing] Copyright (c) 2000-2003 Ovid Technologies, Inc. Version: rel5.2.0, SourceID 1.6922.1.73Ovid Technologies, Inc. Kaplan-Meier curves of cumulative risk of recurrent stroke or death stratified by baseline PFO status. Homma: Circulation, Volume 105(22).June 4, 2002.2625-2631 Patent foramen ovale In Cryptogenic Stroke Study (PICSS)

6. Probability That Patients Will Remain Free from Recurrent Stroke or TIA The log-rank test was used to calculate the P value. Mas: N Engl J Med, Volume 345(24).December 13, 2001.1740-1746

7. Meissner, I. et al. J Am Coll Cardiol 2006;47:440-445 Kaplan-Meier estimate of survival free of cerebrovascular events in 577 subjects according to TEE presence of patent foramen ovale (PFO) SPARC Mayo METHODS: The use of transesophageal echocardiography to identify PFO was performed by a single echocardiographer using standardized definitions in 585 randomly sampled, Olmsted County (Minnesota) subjects age 45 years or older participating in the Stroke Prevention: Assessment of Risk in a Community (SPARC) study.

8. PICSS 2-Year Stroke or Death Rate Warfarin versus Aspirin N=203 (P=0.49) N=398 (P=0.40)N=98 (P=0.28)N=152 (P=0.16) Homma S et al. Circulation. 2002;105:2625-2631. 13.20% 17.40% 17.90% 16.30% 16.50% 13.40% 9.50% 8.30% 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% With PFONo PFOWith PFO (cryptogenic)No PFO (cryptogenic) ASA Warfarin

9. PFO & Stroke: Metanalysis Outcomes Transcatheter Closure vs. Medical Therapy of PFO and presumed Paradoxical event: A systematic review. Landzberg, et al. Annals of Internal Medicine 2003 Recurrent event rates @ 1 Yr. Complication ratesKey Data Weaknesses Medical Therapy3.8 – 12.0%Major: 1%/yr on warfarin Poor match to PFO population. Significant variation in INR targets. Catheter Closure0% - 4.9%Major: 1.5% Minor: 7.9% Significant selection bias. Significant variation in post implant pharm.

10. The CardioSEAL Septal Occlusion System is indicated for closure of a PFO in: Patients with recurrent cryptogenic stroke due to presumed paradoxical embolus through the PFO who have failed medical therapy. Cryptogenic stroke is defined as a stroke occurring in the absence of potential phanerogenic, cardiac, pulmonary, vascular, or neurological sources. Conventional drug therapy is defined as a therapeutic INR on oral anticoagulants. The effectiveness of this device in this indication has not been demonstrated. HDE did not include TIA, migraine, or first stroke and required warfarin failure *HDE withdrawn by CMS October 2006 with no impact on CLOSURE recruitment rate What WAS* the HDE Indication for PFO Device Closure?

12. CLOSURE I Cumulative Enrollment (87 sites) HDE removed 10/06 HDE 2/00 Original N = 1600 Revised N = 900 N revised

16. Randomization Randomization Randomization 1 : 1 STARFlex® Closure (within 30 Days) 6 Months Aspirin and Clopidigrel followed by 18 Months Aspirin Best Medical Therapy 24 Months Aspirin Or Warfarin Or Combination Between June 23, 2003 and October 24, 2008, 909 patients were randomized at 87 sites in the United States and Canada. Block randomization with stratification by study site and by the presence or absence of an ASA viewed by TEE. N = 909 N=447N=462

17. 17 STARFlex® Double umbrella comprised of MP35N framework with attached polyester fabric 23mm, 28mm, 33mm

23. STARFlex Technical Success STARFlex n=402 95% CI Procedural success90.0%(86.7% - 92.8%) Thrombus by TEE 1.0% (n=4; stroke in 2 at days 4, 52) Effective closureNo recurrent stroke or TIA in patients with residual leaks TEE 6 mos86.1% closed(82.1% - 89.4%) TEE 12 mos86.4% closed(82.5% - 89.8%) TEE 24 mos 86.7% closed(82.8% - 90.0%) Procedural success was defined as successful delivery of one or more STARFlex devices to the site during the index procedure, deployment of the device at the intended site, and removal of the delivery system without a major procedural complication prior to discharge. Effective closure was defined as procedural success with either grade 0 (none) or 1 (trace) residual shunt by TEE.

24. Recurrent DWMR+ infarcts (n= 7/12; wnl 2; not done 3) Afib 3/ LA clot 1/ heart cath 1/ ASO 1 5/7 different area from index 4/7 single territory 2/7 multiple same territory 1/7 multiple territories Afib/Laclot on day16/stroke day 52 Multiple punctate Afibflutter/CVA day 22 DM/CABG/valve/CVA day 627 indexACA heart cath with 3 stents on day 232 PAF/valve disease/day 238 LA clot on TEE day 4 Multiple punctate Age 60 multiple TIA spells/30 sec focal with DW+/TEE neg Index punctate MCA Etiology unclear StarFlex Arm

25. (n= 9/13; WNL 4: retinal 1/IV tpa 1/minor sxs >24hr ?? migraine 2 6/9 different territory than index ; 5/9 multiple infarcts same territory; 1/9 multiple territories Age 53/Day 635/ASO/LCEA Age 42/index R parietal /recur L parietal day150 Switch to warfarin/ ?paradoxical Day 15/htn/hpl/mitral regurg/ possible extension/age 50 Age 42/day 146/migraine/clinical TIA/NIH 0/warfarin/?paradoxical Age 31/migraine/day 367 Index cerebellar/ ? coincidental Age 59/day 143/htn;smoker;hpl NIH 3 Age 60/migraine with aura/ Day 143sudden left fingers only NIH 0/old lac unes / Age 35/d1y 122/migraine/ clinical TIA NIH 0 / A ngio neg/ multiple DW+ BG,IC,cerebellum ?paradoxical Age 43/day 32/ multiple subcortical/ ? MS ? Vasculitis Clinical TIA Medical Arm - Recurrent DW+ Infarcts

26. SetCharacteristicP value ITT≤ 500.14* ITT≤ 50 minus all subsets0.61* ITT<400.10* ITT<40 minus all subsets0.40* ITTNo HTN history0.71 ITTIndex crypto stroke minus subcortical0.54* ITTNo reported afib0.10 PP≤ 500.11* PP≤ 400.06* PP< 50 minus all subsets0.62* PP< 40 minus all subsets0.40* PPNo HTN history0.60 PPIndex crypto stroke minus subcortical0.62* PPNo reported afib0.09 *Adjusting performed using Cox Proportional Hazard Regression and adjusting for related patient characteristics including: age, atrial septal aneurysm, prior TIA/CVA, smoking, hypertension, hypercholesterolemia, subcortical infarcts. ITT = Intent to Treat. PP = Per Protocol Exploratory Paradoxical Embolism Analyses 2 Year Composite Primary Endpoint

27. CONCLUSIONS CLOSURE I is the first completed, prospective, randomized, independently adjudicated PFO device closure studyCLOSURE I is the first completed, prospective, randomized, independently adjudicated PFO device closure study Superiority of PFO closure with STARFlex® plus medical therapy over medical therapy alone was not demonstratedSuperiority of PFO closure with STARFlex® plus medical therapy over medical therapy alone was not demonstrated –no significant benefit related to degree of initial shunt –no significant benefit with atrial septal aneurysm –insignificant trend (1.8%) favoring device driven by TIA –2 year stroke rate essentially identical in both arms (3%) Major vascular (procedural) complications in 3% of device armMajor vascular (procedural) complications in 3% of device arm Significantly higher rate of atrial fibrillation in device arm (5.7%)Significantly higher rate of atrial fibrillation in device arm (5.7%) –60% periprocedural

28. CONCLUSIONS Alternative explanation unrelated to paradoxical embolism present in 80% of patients with recurrent stroke or TIAAlternative explanation unrelated to paradoxical embolism present in 80% of patients with recurrent stroke or TIA –cryptogenic stroke and TIA include multiple etiologies –in many patients with cryptogenic stroke or TIA a PFO may be coincidental –diagnostic criteria for paradoxical embolism are imprecise Percutaneous closure with STARFlex® plus medical therapy does not offer any significant benefit over medical therapy alone for the prevention of recurrent stroke or TIA in patients < age 60 presenting with cryptogenic stroke or TIA and a PFOPercutaneous closure with STARFlex® plus medical therapy does not offer any significant benefit over medical therapy alone for the prevention of recurrent stroke or TIA in patients < age 60 presenting with cryptogenic stroke or TIA and a PFO –initial medical therapy appropriate in most patients –device specific complications need further study but not likely to explain CLOSURE I results by themselves –potential efficacy of PFO device closure in better defined patient subgroups requires further study

29. NMT Medical, Inc. Assigns All of Its Assets for the Benefit of Creditors Company Release - 04/19/2011 16:05 BOSTON, MA -- (MARKET WIRE) -- 04/19/11 -- NMT Medical, Inc. (OTCQB: NMTI) (PINKSHEETS: NMTI) today announced that, despite the Company's efforts to obtain additional financing and identify potential strategic transactions, it has failed to raise additional funds or enter into such strategic transaction and, therefore, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law (the "Assignment"). The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Company previously disclosed that it did not have resources to sufficiently fund its continuing business operation and additional capital was required to remain a going concern, and the Company had been seeking strategic alternatives, including financings, recapitalization, sale or disposition of one or more corporate assets, a potential merger and/or a strategic business combination, with various third parties over the course of the past year. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. For creditors and other affected parties of NMT Medical, Inc. all inquiries related to this action should be addressed to Joseph F. Finn, Jr. at Finn, Warnke and Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481 (781-237-8840). Following the liquidation of the Company's assets and distribution of proceeds by the assignee, the Company does not expect that there will be any proceeds for distribution to the Company's stockholders. As part of the Assignment, the Company has terminated the employment of all of its employees. This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, expectations concerning the transfer of all of the Company's Assets to an assignee under and Assignment for the Benefit of Creditors and matters relating to the payment of creditors. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Source: NMT Medical

30. RESPECT Amplatzer ® Occluder REDUCE Clinical Study HELEX R occluder

31. RESPECT

32. PC TRIAL

33. CLOSURE v RESPECT v PC CLOSURE n=909 RESPECT n=980 PC N=414 InclusionTIA, stroke (MR+”TIA”) stroke (MR+”TIA”)“TIA” (MR+) stroke, peripheral DeviceStarflex clamshell Amplatzer plug Amplatzer plug Medicalaspirin warfarin aspirin, clopidogrel, aggrenox warfarin aspirin, ticlopidine, clopidogrel,warfarin Outcome2 years TIA/stroke 8 years Event driven 4 years “TIA”/stroke/ peripheral Intent to Treat Primary result negative

34. PFO Trials: What Went Wrong The question implies we knew the answer –preconceived biases were not confirmed Off label bias caused major recruitment problems –need to link device IND with RCT (eg stents) Industry disappointed –NMT went bankrupt –St Jude FDA pending –market smaller than industry (and interventionalists) had hoped

35. PFO Trials: What Went Wrong Any benefit of device likely small –device specific (thrombus, erosion, afib, residual shunt) –subgroup specific –long followup required –difficult (? impossible) to power a single trial Best medical therapy is unknown –may be subgroup specific like device –antiplatelet versus antithrombotic role of new antithrombotics unknown

36. PFO Trials: What Went Wrong What endpoint? –only CLOSURE included classic TIA endpoint well defined TIA versus ill defined spell –but all 3 trials included imaging positive “TIA” early MR not routine for TIA Evaluation of cryptogenic stroke not standardized –cortical v subcortical infarcts –“hypercoagulopathy” –atrial fibrillation

37. PFO Trials: What Went Right PFO coincidental in many patients with TIA or stroke –indiscriminate device closure halted –annual stroke risk is low –patient selection criteria being refined PFO is more likely related in some patients compared to others ROPE –evaluation of cryptogenic stroke being reassessed

39. “The margin of potential benefit for PFO closure is narrow.”

40. Variables negatively associated with the presence of a PFO included: age (odds ratio [OR] = 0.97 per 1 year increase, p <0.0001); diabetes (OR= 0.65, p < 0.001); hypertension (OR =0.68, p < 0.0001); smoking (OR = 0.70, p<0.60); prior stroke or TIA (OR = 0.78, p=0.04). Cortical stroke on neuroimaging (OR = 1.46, p < 0.001) was also associated with PFO. Based on this, a simple index was created in which the absence of each stroke risk factor was assigned a point, with age dichotomized at 50 years. PFO prevalence in each stratum is shown in the table for patients < age 60, i.e. the subset of patients likely to be considered for PFO closure trials. Risk of Paradoxical Embolism (RoPE) Score Kent D etal Stroke. 2012;43:A84 6single subcortical lacune